Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine

Neoplasia

Volumn 14, Issue 1, 2012, Pages 65-73

  Glinskii, Olga V ^a,b   Sud, Sudha ^c   Mossine, Valeri V ^a   Mawhinney, Thomas P ^a   Anthony, Douglas C ^a,d   Glinsky, Gennadi V ^e   Pienta, Kenneth J ^c   Glinsky, Vladislav V ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LACTULOSE LEUCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CELL ADHESION; CELL AGGREGATION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM; HUMIDIFIER; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING;

EID: 84857024314     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111544     Document Type: Article

References (47)

1. Siegel R, Ward E, Brawley O, and Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212-236.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
3. Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Siddiqui J, Han B, Cao X, et al. (2011). Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 17, 3924-3932.
4. Rubens RD (1998). Bone metastases-the clinical problem. Eur J Cancer 34, 210-213.
5. Roodman GD (2004). Mechanisms of bone metastasis. N Engl J Med 350, 1655-1664.
6. Tantivejkul K, Kalikin LM, and Pienta KJ (2004). Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91, 706-717.
7. Glinsky VV (2006). Intravascular cell-to-cell adhesive interactions and bone metastasis. Cancer Metastasis Rev 25, 531-540.
8. Lehr JE and Pienta KJ (1998). Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90, 118-123.
9. Glinsky VV, Glinsky GV, Rittenhouse-Olsen K, Huflejt ME, Glinskii OV, Deutscher SL, and Quinn TP (2001). The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61, 4851-4857.
10. Khaldoyanidi SK, Glinsky VV, Sikora L, Glinskii AB, Mossine VV, Quinn TP, Glinsky GV, and Sriramarao P (2003). MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem 278, 4127-4134.
11. Shekhar MP, Nangia-Makker P, Tait L, Miller F, and Raz A (2004). Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 165, 1931-1941.
12. Heimburg J, Yan J, Morey S, Wild L, Glinskii OV, Huxley VH, Klick R, Roy R, Glinsky VV, and Rittenhouse-Olson K (2006). Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 8, 939-948.
13. Zou J, Glinsky VV, Landon LA, Matthews L, and Deutscher SL (2005). Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 26, 309-318.
14. Heimburg-Molinaro J, Almogren A, Morey S, Glinskii OV, Roy R, Wilding GE, Cheng RP, Glinsky VV, and Rittenhouse-Olson K (2009). Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen. Neoplasia 11, 780-792.
15. Glinskii OV, Turk JR, Pienta KJ, Huxley VH, and Glinsky VV (2004). Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumor cells. J Physiol 554(pt 1), 89-99.
16. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, and Glinsky VV (2005). Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 7, 522-527.
17. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, and Quinn TP (2003). Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 63, 3805-3811.
18. Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, et al. (2007). Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelium. Neoplasia 9, 662-670.
19. Glinsky VV, Kiriakova G, Glinskii OV, Mossine VV, Mawhinney TP, Turk JR, Glinskii AB, Huxley VH, Price JE, and Glinsky GV (2009). Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia 11, 901-909.
20. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, and Raz A (2002). Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94, 1854-1862.
21. Glinsky GV, Mossine VV, Price JE, Bielenberg D, Glinsky VV, Ananthaswamy HN, and Feather MS (1996). Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs. Clin Exp Metastasis 14, 253-267.
22. Glinsky GV, Price JE, Glinsky VV, Mossine VV, Kiriakova G, and Metcalf JB (1996). Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res 56, 5319-5324.
23. Platt D and Raz A (1992). Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 84, 438-442.
24. Inohara H and Raz A (1994). Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11, 527-532.
25. Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V, and Raz A (1995). Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87, 348-353.
26. Inohara H and Raz A (1995). Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 55, 3267-3271.
27. Kuwabara I and Liu FT (1996). Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol 156, 3939-3944.
28. Inohara H, Akahani S, Koths K, and Raz A (1996). Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 56, 4530-4534.
29. Yu LG (2007). The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J 24, 411-420.
30. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, and Raz A (2000). Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156, 899-909.
31. Fukushi J, Makagiansar IT, and Stallcup WB (2004). NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and α3β1 integrin. Mol Biol Cell 15, 3580-3590.
32. Nakahara S, Oka N, and Raz A (2005). On the role of galectin-3 in cancer apoptosis. Apoptosis 10, 267-275.
33. Giguère D, Bonin MA, Cloutier P, Patnam R, St-Pierre C, Sato S, and Roy R (2008). Synthesis of stable and selective inhibitors of human galectins-1 and -3. Bioorg Med Chem 16, 7811-7823.
34. Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D'Egidio M, Piccolo E, Tinari N, Nifantiev N, and Iacobelli S (2006). Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16, 210-220.
35. Tejler J, Skogman F, Leffler H, and Nilsson UJ (2007). Synthesis of galactosemimicking 1H-(1,2,3-triazol-1-yl)-mannosides as selective galectin-3 and 9N inhibitors. Carbohydr Res 342, 1869-1875.
36. Fort S, Kim HS, and Hindsgaul O (2006). Screening for galectin-3 inhibitors from synthetic lacto-N-biose libraries using microscale affinity chromatography coupled to mass spectrometry. J Org Chem 71, 7146-7154.
37. Tejler J, Leffler H, and Nilsson UJ (2005). Synthesis of O-galactosyl aldoximes as potent LacNAc-mimetic galectin-3 inhibitors. BioorgMed Chem Lett 15, 2343-2345.
38. Cumpstey I, Sundin A, Leffler H, and Nilsson UJ (2005). C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions. Angew Chem Int Ed Engl 44, 5110-5112.
39. Salameh BA, Cumpstey I, Sundin A, Leffler H, and Nilsson UJ (2010). 1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors. Bioorg Med Chem 18, 5367-5378.
40. Kalikin LM, Schneider A, Thakur MA, Fridman Y, Griffin AB, Dunn RL, Rosol TJ, Shah RB, Rehemtulla A, McCauley LK, et al. (2003). In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther 2, 17-21.
41. Loberg RD, Day LL, Dunn R, Kalikin LM, and Pienta KJ (2006). Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8, 69-78.
42. Mossine VV, Glinsky VV, and Mawhinney TP (2008). Food-related carbohydrate ligands for galectins. In Galectins. AA Klyosov, ZJ Witczak, and D Platt (Eds). Wiley, London, UK. pp. 235-270.
43. Fukumori T, Kanayama HO, and Raz A (2007). The role of galectin-3 in cancer drug resistance. Drug Resist Updat 10, 101-108.
44. Nangia-Makker P, Nakahara S, Hogan V, and Raz A (2007). Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr 39, 79-84.
45. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, et al. (2005). A novel carbohydratebased therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 65, 8350-8358.
46. Wang Y, Nangia-Makker P, Balan V, Hogan V, and Raz A (2010). Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis 1, e101.
47. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, and Muschel RJ (2000). Intravascular origin of metastasis from the proliferation of endotheliumattached tumor cells: a new model for metastasis. Nat Med 6, 100-102.